Buy 5 or More Products! Save 25% On Total.
 Buy 3 or More Products! Save 10% On Total.
 Free Shipping! No Minimum Order.

Lynparza (Olaparib) is indicated for treatment(s) of:

I. Ovarian Cancer
II. Metastatic Breast Cancer
III. Pancreatic cancer

a. I only
b. III only
c. I and II only
d. II and III only
e. All

Answer: (e). All. Lynparza (Olaparib) is an inhibitor of the mammalian polyadenosine 5'-diphosphoribose polymerase (PARP) enzyme. Lynparza (Olaparib) tablets for oral administration contain 100 mg or 150 mg of Olaparib.

It is indicated for treatments of:
1. First-Line Maintenance Treatment Of BRCA-Mutated Advanced Ovarian Cancer
2. Maintenance Treatment Of Recurrent Ovarian Cancer
3. Advanced gBRCA-Mutated Ovarian Cancer After 3 Or More Lines Of Chemotherapy
4. Germline BRCA-Mutated HER2-Negative Metastatic Breast Cancer
5. Maintenance Treatment Of gBRCA-Mutated Pancreatic cancer

The recommended dose of Lynparza (Olaparib) is 300 mg (two 150 mg tablets) taken orally twice daily, with or without food, for a total daily dose of 600 mg.

Myelodysplastic Syndrome, Acute Myeloid Leukemia, Pneumonitis, fatigue, nausea, vomiting and fatal toxicity are reported side effects of drug.

Try our Naplex QBank. **Please note: This type of question will not show up in an MPJE. We are just posting to MPJE group for knowledge.